Serum Anti-Gliadin IgG (Anti-DGP) Test at Chughtai Lab

Serum Anti-Gliadin IgG (Anti-DGP IgG) at Chughtai Lab

The Serum Anti-Gliadin IgG (Anti-Deamidated Gliadin Peptide IgG) test is a highly specialized immunological assay utilized primarily for the diagnosis and monitoring of celiac disease and gluten-sensitive enteropathy. Offered across the extensive diagnostic network of Chughtai Lab in Pakistan, this laboratory investigation plays a pivotal role in identifying autoimmune responses triggered by gluten ingestion. Gluten, a protein composite found in wheat, barley, and rye, can cause severe small intestinal mucosal damage in genetically susceptible individuals. The Anti-DGP IgG test specifically measures the concentration of IgG antibodies directed against deamidated gliadin peptides, which are formed when the enzyme tissue transglutaminase (tTG) modifies gliadin in the gut mucosa.

How the test works relies on advanced Enzyme-Linked Immunosorbent Assay (ELISA) or Chemiluminescent Immunoassay (CLIA) technologies. When a patient with celiac disease consumes gluten, their immune system recognizes deamidated gliadin as a foreign invader, producing specific immunoglobulin G (IgG) antibodies. By detecting these antibodies in the blood serum, Chughtai Lab provides clinicians with crucial diagnostic data. This test is particularly valuable because it evaluates the systemic immunological response that directly correlates with small intestinal inflammation, villous atrophy, and crypt hyperplasia.

The clinical importance of the Serum Anti-Gliadin IgG test cannot be overstated. It serves as an essential diagnostic tool for patients who have selective IgA deficiency—a condition that occurs in 2% to 3% of patients with celiac disease, rendering standard IgA-based tests (like Anti-tTG IgA) false-negative. Furthermore, the Anti-DGP IgG test exhibits superior diagnostic sensitivity and specificity in pediatric populations, particularly in infants and toddlers under the age of two, whose immune systems may not yet produce detectable levels of other celiac-related antibodies. By choosing Chughtai Lab, patients across Pakistan gain access to international-standard pathology services that ensure accurate, reproducible, and timely results.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the clinical accuracy of the Serum Anti-Gliadin IgG test at Chughtai Lab, patients must adhere to specific preparation guidelines. Because this test measures the immune system’s reaction to gluten, the most critical preparation requirement is that the patient must maintain a gluten-containing diet in the weeks leading up to the blood draw. If a patient has already transitioned to a strict gluten-free diet (GFD), the levels of Anti-DGP IgG antibodies may decline significantly, potentially leading to a false-negative result. Clinicians typically recommend consuming gluten-containing foods, such as bread, pasta, or cereals, daily for at least 4 to 6 weeks prior to testing.

• Gluten Consumption: Do not start a gluten-free diet before the test. Ensure regular gluten intake for several weeks as advised by your gastroenterologist to maintain detectable antibody levels.
• Fasting Requirements: Routine fasting is generally not required for the Serum Anti-Gliadin IgG test. However, if other concurrent blood tests (such as a lipid profile or fasting blood sugar) are ordered alongside, fasting may be necessary.
• Medication Review: Inform your healthcare provider and the phlebotomist at Chughtai Lab about any immunosuppressive medications, corticosteroids, or chemotherapy you are currently undergoing, as these can suppress antibody production and affect test results.
• Hydration: Stay well-hydrated by drinking plenty of water before the blood collection, as this makes venipuncture easier and more comfortable.
• Documentation: Carry your doctor’s prescription and any previous laboratory reports related to gastrointestinal symptoms or autoimmune conditions.

During the Procedure

The Serum Anti-Gliadin IgG test is a standard venipuncture procedure performed by highly trained phlebotomists at Chughtai Lab. The process is quick, safe, and minimally invasive, designed to prioritize patient comfort and sample integrity.

• Patient Positioning: You will be asked to sit comfortably in a phlebotomy chair. The phlebotomist will ask you to extend your arm, usually exposing the antecubital fossa (the inner elbow area).
• Site Selection and Cleansing: The phlebotomist will inspect your veins and select a suitable vein for blood collection. The chosen site is then thoroughly cleansed with an antiseptic swab (usually 70% isopropyl alcohol) to prevent any microbial contamination.
• Tourniquet Application: A sterile elastic tourniquet is tied around your upper arm to restrict blood flow temporarily, causing the veins to swell and become more visible and accessible.
• Venipuncture: A sterile, single-use, fine-gauge needle is gently inserted into the vein. You may feel a brief, mild pinch or prick. The blood is collected into a gold-top or red-top serum separator tube (SST).
• Sample Processing: Once the required volume of blood is collected, the needle is carefully withdrawn, and a sterile cotton ball or adhesive bandage is applied to the puncture site to stop any minor bleeding.
• Duration: The entire blood collection process takes less than 5 minutes.
• Safety Considerations: Chughtai Lab strictly adheres to international biosafety standards. All needles and syringes are sterile, single-use, and disposed of immediately in designated sharps containers to eliminate any risk of cross-contamination.

When is a Serum Anti-Gliadin IgG (Anti-DGP IgG) Performed?

Suspected Celiac Disease in IgA-Deficient Patients

Selective IgA deficiency is highly prevalent among individuals with celiac disease compared to the general population. Standard screening tests, such as Anti-Tissue Transglutaminase IgA (Anti-tTG IgA) and Anti-Endomysial Antibody IgA (EMA IgA), rely on the presence of normal systemic IgA levels. If a patient is IgA deficient, these tests will yield false-negative results, potentially delaying crucial medical intervention. In such clinical scenarios, physicians request the Serum Anti-Gliadin IgG (Anti-DGP IgG) test. Because it measures IgG-class antibodies, it bypasses the IgA deficiency limitation, providing a highly reliable and accurate diagnostic alternative to confirm or rule out gluten-sensitive enteropathy.

Chronic Gastrointestinal Symptoms

When patients present with persistent, unexplained gastrointestinal distress, the Serum Anti-Gliadin IgG test is frequently indicated. Chronic symptoms such as long-standing diarrhea, recurrent abdominal pain, persistent bloating, excessive flatulence, and nausea can indicate underlying mucosal damage in the small intestine. These symptoms often stem from the malabsorption of nutrients caused by the autoimmune destruction of intestinal villi. By measuring Anti-DGP IgG levels, gastroenterologists can determine whether these chronic symptoms are rooted in an autoimmune reaction to gluten, helping to differentiate celiac disease from other conditions like irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD).

Pediatric Growth Failure and Malabsorption

In infants and young children, celiac disease often manifests as failure to thrive, unexplained weight loss, short stature, delayed puberty, and severe nutritional deficiencies like iron-deficiency anemia or vitamin D deficiency. Young children under two years of age often do not produce robust levels of Anti-tTG IgA antibodies, making the Anti-DGP IgG test a superior diagnostic tool in pediatric medicine. Pediatricians request this test to investigate chronic digestive issues, abdominal distension, and developmental delays, as early detection and dietary modification are vital to prevent long-term growth impairment and bone mineralization issues.

Monitoring Gluten-Free Diet Compliance

For patients already diagnosed with celiac disease, the Serum Anti-Gliadin IgG test serves as an excellent tool for monitoring compliance with a gluten-free diet (GFD). After eliminating gluten from the diet, the levels of Anti-DGP IgG antibodies should gradually decline and eventually return to normal (negative) levels, reflecting mucosal healing. If a patient’s antibody levels remain elevated during follow-up testing at Chughtai Lab, it indicates either intentional or accidental ongoing exposure to gluten. This assists clinical dietitians and gastroenterologists in identifying hidden sources of gluten in the patient’s diet and counseling them effectively.

Screening High-Risk Individuals with Family History

Celiac disease has a strong genetic component, closely linked to HLA-DQ2 and HLA-DQ8 tissue types. Individuals with a first-degree relative (parent, sibling, or child) diagnosed with celiac disease have a significantly higher risk of developing the condition. Additionally, patients with other autoimmune disorders, such as Type 1 Diabetes Mellitus, autoimmune thyroiditis (Hashimoto’s), Down syndrome, or Turner syndrome, are at increased risk. Physicians utilize the Serum Anti-Gliadin IgG test as part of a comprehensive screening panel to detect asymptomatic or silent celiac disease in these high-risk populations, allowing for early dietary intervention before severe mucosal damage occurs.

What Does a Serum Anti-Gliadin IgG (Anti-DGP IgG) Detect?

The Serum Anti-Gliadin IgG (Anti-DGP IgG) test at Chughtai Lab is designed to detect and quantify specific immunological markers associated with gluten sensitivity and celiac disease. Here is a detailed clinical breakdown of what this test detects and its diagnostic implications:

• Deamidated Gliadin Peptide Antibodies: The test specifically detects IgG antibodies that target deamidated gliadin peptides, which are highly specific markers for celiac disease.
• Autoimmune Response to Gluten: It identifies the presence of an active systemic immune response triggered by the ingestion of gluten-containing grains.
• Gluten-Sensitive Enteropathy: Elevated levels indicate a high probability of gluten-sensitive enteropathy, characterized by inflammation of the small intestinal lining.
• Selective IgA Deficiency Support: It detects celiac-specific antibodies in patients who lack systemic IgA, ensuring they are not misdiagnosed due to false-negative IgA tests.
• Pediatric Celiac Disease: It detects early-stage celiac disease in infants and toddlers who may not yet show positive results on standard IgA-based screening panels.
• Active Mucosal Inflammation: High titers of Anti-DGP IgG correlate with active mucosal inflammation and damage within the duodenum and jejunum.
• Villous Atrophy Risk: Strongly positive results indicate a high risk of severe villous atrophy, where the microscopic, finger-like projections of the small intestine are flattened.
• Crypt Hyperplasia: It helps identify patients likely to have crypt hyperplasia, an anatomical change in the intestinal lining associated with chronic celiac disease.
• Dietary Non-Compliance: Persistent or rising antibody levels in diagnosed patients detect ongoing dietary exposure to gluten, whether accidental or deliberate.
• Dietary Compliance and Healing: A significant decrease or normalization of antibody levels over time detects successful adherence to a gluten-free diet and subsequent mucosal healing.
• Malabsorption Etiology: It helps detect whether nutritional deficiencies, such as refractory iron-deficiency anemia, are caused by gluten-induced enteropathy.
• Silent or Asymptomatic Celiac Disease: The test detects elevated antibodies in asymptomatic individuals with a strong family history of celiac disease.
• Potential for Dermatitis Herpetiformis: It detects the underlying gluten sensitivity associated with dermatitis herpetiformis, an intensely itchy, blistering skin manifestation of celiac disease.
• Immune System Activation: It measures the specific activation of the adaptive immune system, particularly the IgG pathway, against dietary antigens.
• Need for Small Bowel Biopsy: Highly elevated levels detect the clinical necessity for an upper gastrointestinal endoscopy and duodenal biopsy to confirm a celiac disease diagnosis.
• Refractory Celiac Disease Risk: In rare cases, persistently high levels despite a strict gluten-free diet help clinicians investigate refractory celiac disease.
• Cross-Reactive Immunological Activity: It detects the specific binding of IgG antibodies to modified gliadin, minimizing cross-reactivity with non-specific native gliadin antibodies.
• Epithelial Barrier Dysfunction: Elevated levels reflect increased intestinal permeability, allowing gliadin peptides to cross the epithelial barrier and trigger an immune response.
• Systemic Autoimmune Tendencies: It helps identify patients who may have a broader predisposition to autoimmune diseases due to shared genetic and immunological pathways.
• Response to Gluten Challenge: In patients undergoing a diagnostic gluten challenge, the test detects the re-emergence of celiac-specific antibodies.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is renowned across Pakistan for its state-of-the-art diagnostic infrastructure and rapid reporting systems. The Serum Anti-Gliadin IgG (Anti-DGP IgG) test is processed using fully automated immunoassay platforms that ensure maximum precision and minimal turnaround time. Typically, the test results are verified by consultant pathologists and made available within 24 to 48 hours of sample collection.

Patients can access their diagnostic reports conveniently through multiple digital channels. Once the report is finalized, an automated SMS notification containing a direct download link is sent to the patient’s registered mobile number. Reports can also be accessed and downloaded via the official Chughtai Lab website by entering the patient’s case number and password, or through the user-friendly Chughtai Lab Mobile App. For patients who prefer physical copies, reports can be collected from any Chughtai Lab collection center nationwide, or delivered directly to their doorstep through the lab’s home delivery service.

Serum Anti-Gliadin IgG (Anti-DGP IgG) Findings Overview

The following table outlines the clinical parameters evaluated during the Serum Anti-Gliadin IgG test, along with normal and possible abnormal findings:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Serum Anti-DGP IgG Antibody Level	Negative (typically < 20 U/mL, depending on specific assay calibrators)	Positive (elevated titers, e.g., ≥ 20 U/mL), indicating active immunological response to gluten
Small Intestinal Mucosa State	Intact intestinal villi, normal crypt depth, and absence of intraepithelial lymphocytosis	Villous atrophy, crypt hyperplasia, and mucosal inflammation indicative of celiac disease
Dietary Compliance Status	Undetectable or baseline antibody levels in patients adhering to a strict gluten-free diet	Persistently elevated antibody levels, indicating accidental or deliberate gluten ingestion
Pediatric Diagnostic Utility	Negative antibody levels in healthy infants and young children	Elevated IgG antibodies, providing high diagnostic accuracy in children under 2 years of age
IgA Deficiency Context	Normal systemic IgA levels with negative IgG antibodies	Elevated IgG antibodies in patients with selective IgA deficiency, bypassing false-negative IgA screens
Malabsorption Markers Correlation	Normal absorption of iron, folate, vitamin D, and B12; healthy bone density and growth	Malabsorption-related anemia, osteopenia, or failure to thrive associated with high antibody titers
Clinical Symptom Association	Absence of gluten-induced gastrointestinal or extra-intestinal symptoms	Chronic diarrhea, abdominal pain, bloating, fatigue, or dermatitis herpetiformis correlating with high titers
Histopathological Correlation	Marsh Stage 0 (normal mucosa) on subsequent duodenal biopsy	Marsh Stage 1 to 3 (ranging from infiltrative to destructive villous atrophy) on biopsy

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Serum Anti-Gliadin IgG (Anti-DGP IgG)?

• Experienced Healthcare Professionals: Chughtai Lab boasts a team of highly qualified consultant pathologists, immunologists, and laboratory technologists who oversee all testing procedures.
• Patient-Focused Care: The lab prioritizes patient comfort, safety, and convenience, ensuring a seamless diagnostic experience from sample collection to report delivery.
• Quality Diagnostic Services: Operating with state-of-the-art, fully automated immunoassay platforms, Chughtai Lab ensures the highest level of analytical precision and reproducibility.
• Professional Reporting: Reports are verified by expert pathologists and include clear reference ranges, helping clinicians make accurate and timely diagnostic decisions.
• Modern Diagnostic Approach: By utilizing advanced ELISA and CLIA methodologies for Anti-DGP IgG detection, the lab offers international-standard diagnostic accuracy.
• Comfortable Environment: All Chughtai Lab collection centers across Pakistan are designed to provide a clean, hygienic, and welcoming environment for patients of all ages.
• Convenient Location: With a vast network of hundreds of collection centers nationwide, patients can easily find a Chughtai Lab facility near their home or workplace.
• Commitment to Accurate Diagnosis: Chughtai Lab participates in rigorous external quality assurance programs and proficiency testing, maintaining its reputation as Pakistan’s trusted diagnostic partner.